UPDATE: Ascendiant Capital Lowers PT on Biolase on Good Market Position
July 03, 2013 at 10:12 AM EDT
In a report published Wednesday, Ascendiant Capital analyst Keay Nakae reiterated a Buy rating on Biolase (NASDAQ: BIOL ), but lowered the price target from $6.50 to $5.50. In the report, Ascendiant Capital noted, “We continue to believe that Biolase is well positioned in the dental laser market. The stock
